This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Double test

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The double test is now obsolete as a screening tool in the UK.

The recommended method of screening for Down's syndrome is using the Combined Test.

Combined screening can be carried out in the first trimester and up to 14 weeks and 1 day of pregnancy.

Women who present too late for combined screening should be offered quadruple testing in the second trimester of pregnancy.

For more information: NHS Fetal Anomaly Screening Programme (NHS FASP) www.fetalanomaly.screening.nhs.uk

References:

  • 1. NICE. Antenatal care: routine care for the healthy pregnant woman. England: NHS National Institute for Health and Clinical Excellence; 2008 Mar. Report No.: Clinical guidelines CG62.
  • 2. NHS Fetal Anomaly Screening Programme. Antenatal screening - working standards for Down's syndrome screening 2007. NHS FASP; 2007.
  • 3. NHS Fetal Anomaly Screening Programme. Consent standards for screening fetal anomalies during pregnancy 2007. NHS FASP; 2007.
  • 4. NHS Fetal Anomaly Screening Programme. Screening for Down's syndrome: UK NSC Policy recommendations 2011-2014 Model of Best Practice. Department of Health; 2011.
  • 5. Kirwan D, NHS FASP. 18+0 to 20+6 weeks fetal anomaly scan -National standards and guidance for England 2010. Exeter, England: NHS Fetal Anomaly Screening Programme; 2010.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.